[Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment].
An aim of the study was to investigate the efficacy and safety of noojerone (memantine) in patients with cognitive impairment comorbid to brain ischemia, stages II-III. The main group (30 patients, aged 64-86 years) was treated with noojerone in addition to standard therapy according to dosage scheme during 6 months. The control group (15 patients, aged 61-78 years) received standard therapy only. Patients underwent somatic and neurological examinations, along with neuropsychological testing (MMSE, FAB and other tests). The use of noojerone in complex treatment decreased cognitive impairment in the main group compared to the control one. The most distinct changes were noted on MMSE. Statistically significant changes appeared during the 12th week. The maximal effect was observed when the drug was applied during 6 months. Noojerone was well-tolerated by the patients.